Avid Bioservices, Inc.

Avid Bioservices is a dedicated CDMO for development and CGMP manufacturing of biologics, with 30+ years of experience. Specializing in monoclonal antibodies and recombinant proteins, it provides services from process development through large-scale clinical and commercial manufacturing, including analytical development, bulk packaging, and regulatory support. In 2025, it was acquired by GHO Capital and Ampersand Capital Partners for approximately $1.1 billion.